3-V Biosciences has changed its name to Sagimet Biosciences after closing a series E round backed by strategic partner Ascletis at $25m.
Sagimet Biosciences, a US-based developer of treatments for fatty acid synthase, increased its series E round to $25m on Monday following an extension led by hepatitis C drug developer Ascletis Pharma.
Qianhai Ark Investment, New Enterprise Associates (NEA) and Kleiner Perkins also took part in the extension, all four investors having contributed to the round’s $18m first tranche in February this year.
Formerly known as 3-V Biosciences, Sagimet is working on therapeutics that are intended to target dysfunctional metabolic…
